Grünenthal considers funding options after reports of scrapped leveraged debt sale

pills adobe stock 575x375 pharmaceuticals
By Mike Turner
17 Feb 2021

Grünenthal, the German pain relief medicine maker, has extended the maturities on €535m of term loan facilities, telling GlobalCapital it is open to various financing options, after a press report saying investors had shunned a new euro leveraged loan.

Grünenthal planned to raise hundreds of millions of euros of debt but scrapped the deal due to a lack of interest as investors do not want to be seen financing an opioid producer, Bloomberg reported. Grünenthal produces tramadol, a widely used opioid pain medication.

Instead, the company has lengthened ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial